Orchid BioSciences has appointed James Beery to its board of directors. Currently, he is senior counsel to the law firm Covington & Burling, where he specializes in pharmaceutical and biotechnology matters.
Before joining Covington & Burling in 2002, Beery was senior vice president and general counsel of GlaxoSmithKline. He also was senior vice president of general counsel and corporate secretary of SmithKline Beecham for seven years before the firm was acquired by Glaxo Wellcome in 2000.
Bioreason has named Andrew DePristo president and CEO, the Santa Fe, NM, company said last week.
DePristo comes to the drug discovery informatics company from Amgen, where he was senior director of research and preclinical development information systems. He was also founding president of a GeneData US subsidiary, and also served as vice president of bioinformatics, information technology, and emerging technology at Genome Therapeutics.
DePristo received a PhD in theoretical chemistry from the University of Maryland.
Agilent Technologies has named May Van as vice president and general manager of the consumables and services business in its Life Sciences and Chemical Analysis group, the company said last week.
Van, who joined Hewlett-Packard, Agilent’s parent, in 1997 and remained with Agilent when it spun out in 1999, is being promoted from a position as controller of the consumables and services business. Prior to joining the company, Van was director of finance and administration at Integrated Circuit Systems. She received a bachelor’s of business administration in accounting from Texas Tech University, and an MBA from West Chester University in Pennsylvania, the company said last week.
Genstruct has appointed William Ladd as vice president-discovery systems, the drug-discovery company said last week.
Ladd was most recently senior director of analytic applications at Spotfire. Before joining Spotfire, he was director of bioinformatics methods at Gene Logic. Earlier, he worked in the biological data department at Merck.